Nephritis clinical trials
The registry lists 50 studies for Nephritis across more than 10 countries. 13 are recruiting or about to start. 5 of them are mainly about Nephritis (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-10. Counting its 8 narrower conditions too, such as Lupus Nephritis: 1,023 studies, 356 open.
Get an email when these change. Save the Nephritis studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
Goldfinch Bio, Inc. (3) · Assiut University (2) · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) (2) · La Jolla Pharmaceutical Company (2) · Biohaven Therapeutics Ltd. (2) · Genzyme, a Sanofi Company (2) · Tuen Mun Hospital (2) · Anthera Pharmaceuticals (2)
What is being tested here
Drugs under test in Nephritis studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
All 6, phase 3 first
- Apr 2027A Study of SNP-ACTH (1-39) Gel in Patients With Primary Membranous Nephropathy · Phase 3 · Cerium Pharmaceuticals, Inc.
- Sep 2027Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis · Phase 3 · Novartis Pharmaceuticals
- May 2027Gonadotropin-releasing Hormone Agonist (GnRHa) in Ovarian Preservation in SLE Subjects Receiving Cyclophosphamide as Determined by Questionnaires · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- Jul 2027Study of BHV-1400 in IgA Nephropathy · Biohaven Therapeutics Ltd.
- Sep 2027Characterization of Renal Microvascular Alterations in Patients With Active Urinary Sediment and/or Proteinuria Using Ultrasound Localization Microscopy · University of Erlangen-Nürnberg Medical School
- Nov 2027Atacicept in Multiple Glomerular Diseases · Vera Therapeutics, Inc.
Who these studies take
Of the 11 Nephritis studies recruiting now, 6 (55%) set no upper age limit and 3 (27%) stop at 75 or younger. 1 (9%) take children under 18. 1 (9%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 1 (9%) | 1 (9%) |
| 18 | 10 (91%) | 9 (82%) |
| 30 | 10 (91%) | 9 (82%) |
| 40 | 11 (100%) | 10 (91%) |
| 50 | 11 (100%) | 10 (91%) |
| 65 | 10 (91%) | 9 (82%) |
| 75 | 9 (82%) | 8 (73%) |
| 85 | 8 (73%) | 7 (64%) |
Across all 50 studies, recruiting or not: 48% stop at 75 or younger and 26% at 65; 18% take children; 4% are for women only and 0% for men only; 10% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
What changed recently
From the registry's own updates since Oct 12, 2026.
Started recruiting1
- A Phase 3 Blinded Study of JADE101 in Participants With Immunoglobulin A NephropathyNov 3, 2026NCT07902817
Newly registered1
- A Phase 3 Blinded Study of JADE101 in Participants With Immunoglobulin A NephropathyOct 29, 2026NCT07902817
Studies
Recruiting first, then most recently updated. Showing 50 of 50. search them.
- Gonadotropin-releasing Hormone Agonist (GnRHa) in Ovarian Preservation in SLE Subjects Receiving Cyclophosphamide as Determined by QuestionnairesRecruitingNCT055671981 country
- A Phase 3 Blinded Study of JADE101 in Participants With Immunoglobulin A NephropathyRecruitingNCT07902817Phase 31 country
- A Study of JADE101 in Participants With Immunoglobulin A NephropathyRecruitingNCT07541287Phase 25 countries
- PS-002 for the Treatment of IgA Nephropathy in AdultsRecruitingNCT07182227Phase 1/22 countries
- Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.RecruitingNCT06858319Phase 39 countries
- Atacicept in Multiple Glomerular DiseasesRecruitingNCT06983028Phase 21 country
- A Study of SNP-ACTH (1-39) Gel in Patients With Primary Membranous NephropathyRecruitingNCT05696613Phase 33 countries
- Study of BHV-1400 in IgA NephropathyRecruitingNCT07054684Phase 12 countries
- A Study to Determine if BHV-1400 is Effective and Safe in Adults With IgA NephropathyNot yet recruitingNCT07642050Phase 3
- Characterization of Renal Microvascular Alterations in Patients With Active Urinary Sediment and/or Proteinuria Using Ultrasound Localization MicroscopyRecruitingNCT074690591 country
- The MICRON Study - A Steno 1 SubstudyRecruitingNCT072701721 country
- A Study of Telitacicept in Lupus NephritisRecruitingNCT05680480Phase 21 country
- Renal Survival in Patients with Lupus NephritisNot yet recruitingNCT06588192
- Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus NephritisActive, not recruitingNCT05126277Phase 327 countries
- Safety and Efficacy Study of VIS649 for IgA NephropathyCompletedNCT04287985Phase 215 countries
- A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients With Lupus Nephritis (ZL-1103-013)CompletedNCT05810948Phase 21 country
- A Study of KZR-616 in Patients With SLE With and Without Lupus NephritisCompletedNCT03393013Phase 1/28 countries
- Study of Lademirsen (SAR339375) in Patients With Alport SyndromeTerminatedNCT02855268Phase 27 countries
- S100A8 in Serum and Urine as a New Biomarker in Lupus NephritisCompletedNCT068721381 country
- Individualized Homeopathy to Reduce the Use of Antibiotics in Women With Recurrent Uncomplicated Urinary Tract InfectionsActive, not recruitingNCT05545514Phase 41 country
- Use of Baricitenib to Maintain of RemissionStatus unknownNCT05686746Phase 2/31 country
- A Study of TRPC5 Channel Inhibitor in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change DiseaseTerminatedNCT04387448Phase 21 country
- An Open-Label, Long-term Study of GFB-887 in Patients With Glomerular Kidney DiseasesTerminatedNCT04950114Phase 21 country
- Distribution of Biospecimens From Biorepositories/Biobanks for Research UseWithdrawnNCT038844001 country
- A Study of RG-012 in Subjects With Alport SyndromeCompletedNCT03373786Phase 11 country
- DS Titanium Ligation Clip in Urology (Prostatectomy and Nephrectomy)CompletedNCT048694621 country
- Safety and Efficacy of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Proliferative Lupus NephritisCompletedNCT02547922Phase 217 countries
- Efficacy and Safety of Belimumab in Patients With Active Lupus NephritisCompletedNCT01639339Phase 321 countries
- FIH Ph 1 Study of TRPC5 Channel Inhibitor GFB-887 in Healthy SubjectsCompletedNCT03970122Phase 11 country
- Monoclonal Antibody Treatment for Systemic Lupus ErythematosusCompletedNCT00046774Phase 11 country
- The Iguratimod Effect on Lupus Nephritis (IGeLU)Status unknownNCT02936375Phase 21 country
- Xolair (Omalizumab) for Treatment of Drug-induced Acute Tubulointerstitial Nephritis (AIN)WithdrawnNCT01893658Phase 21 country
- Trial of Rituximab and Mycophenolate Mofetil Without Oral Steroids for Lupus NephritisTerminatedNCT01773616Phase 31 country
- Hydroxychloroquine Sulfate Alleviates Persistent Proteinuria in IgA NephropathyStatus unknownNCT02765594Phase 41 country
- CHABLIS7.5: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus With or Without NephritisTerminatedNCT02514967Phase 31 country
- The Efficacy and Safety of Atacicept in Combination With Mycophenolate Mofetil Used to Treat Lupus NephritisTerminatedNCT00573157Phase 2/35 countries
- Study of LJP 394 (Abetimus Sodium) in Lupus PatientsWithdrawnNCT00390091Phase 21 country
- CHABLIS-SC2: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus With or Without NephritisWithdrawnNCT02074020Phase 3
- The Efficacy and Safety of Calcitriol for the Treatment of Lupus Nephritis and Persistent ProteinuriaWithdrawnNCT00508898Phase 4
- Phenotypic and Genotypic Identification and Characterization of MYH9-related Constitutional ThrombocytopeniaCompletedNCT009252361 country
- A Study to Compare the Efficacy and Safety of Tacrolimus Capsules With Leflunomide Tablets in Lupus Nephritis PatientsTerminatedNCT01342016Phase 31 country
- Safety Study of AMG 811 in Subjects With Systemic Lupus Erythematosus With and Without GlomerulonephritisCompletedNCT00818948Phase 15 countries
- Comparing the Efficacy of Tacrolimus and Mycophenolate Mofetil for the Initial Therapy of Active Lupus NephritisCompletedNCT00371319Phase 41 country
- Low-dose Combination of Mycophenolate Mofetil (MMF) and Tacrolimus (Tac) for Refractory Lupus NephritisCompletedNCT01203709Phase 41 country
- HSP-glomerulonephritis Trial: MP vs CyACompletedNCT00425724Phase 41 country
- Prospective Study Evaluating the Effect of Repository Corticotropin in the Treatment of Various Nephrotic SyndromesCompletedNCT01021540Phase 41 country
- Leflunomide Versus Azathioprine for Maintenance Therapy of Lupus NephritisStatus unknownNCT01172002Not applicable1 country
- Mycophenolate Mofetil (MMF) Versus Intravenous CTX Pulses in the Treatment of Adult Severe HSPNCompletedNCT00301613Not applicable1 country
- TNF Blockade With Remicade in Active Lupus Nephritis WHO Class V (TRIAL )TerminatedNCT00368264Phase 2/33 countries
- Study of LJP 394 in Lupus Patients With History of Renal DiseaseTerminatedNCT00089804Phase 330 countries